Euclidean Capital 13F annual report

Euclidean Capital is an investment fund managing more than $796 billion ran by Joseph Cosmai. There are currently 10 companies in Mr. Cosmai’s portfolio. The largest investments include Spdr Sp 500 Etf Tr and Ishares Tr, together worth $759 billion.

$796 billion Assets Under Management (AUM)

As of 7th August 2024, Euclidean Capital’s top holding is 1,146,979 shares of Spdr Sp 500 Etf Tr currently worth over $624 billion and making up 78.4% of the portfolio value. In addition, the fund holds 2,425,144 shares of Ishares Tr worth $135 billion. The third-largest holding is Foghorn Therapeutics worth $9.05 billion and the next is Oric Pharmaceuticals worth $7 billion, with 989,410 shares owned.

Currently, Euclidean Capital's portfolio is worth at least $796 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Euclidean Capital

The Euclidean Capital office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Joseph Cosmai serves as the Manager at Euclidean Capital.

Recent trades

In the most recent 13F filing, Euclidean Capital revealed that it had opened a new position in Surrozen Inc and bought 87,696 shares worth $960 million.

The investment fund also strengthened its position in Spdr Sp 500 Etf Tr by buying 900,729 additional shares. This makes their stake in Spdr Sp 500 Etf Tr total 1,146,979 shares worth $624 billion.

On the other hand, there are companies that Euclidean Capital is getting rid of from its portfolio. Euclidean Capital closed its position in Spdr Gold Tr on 14th August 2024. It sold the previously owned 1,062,500 shares for $182 billion.

One of the average hedge funds

The two most similar investment funds to Euclidean Capital are Van Cleef Asset Management,inc and Unison Advisors. They manage $795 billion and $797 billion respectively.

Joseph Cosmai investment strategy

Euclidean Capital’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 3.5% of the total portfolio value. The fund focuses on investments in the United States as 50.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $429 million.

The complete list of Euclidean Capital trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Spdr Sp 500 Etf Tr	365.78% 1,146,979	$624,208,911,000	78.43%
Spdr Gold Tr	Closed 1,062,500	$182,165,625,000
Ishares Tr	No change 2,425,144	$135,274,532,000	17.00%
Foghorn Therapeutics Inc.	No change 1,573,761	$9,049,126,000	1.14%
Oric Pharmaceuticals, Inc.	No change 989,410	$6,995,129,000	0.88%
Alector, Inc.	No change 1,307,858	$5,937,675,000	0.75%
Pmv Pharmaceuticals Inc	No change 2,627,643	$4,256,782,000	0.53%
23andme Holding Co	No change 10,243,122	$4,007,109,000	0.50%
Tenaya Therapeutics Inc	No change 1,015,705	$3,148,686,000	0.40%
RAPT Therapeutics, Inc.	No change 657,899	$2,006,592,000	0.25%
Ngm Biopharmaceuticals Inc	Closed 992,168	$1,061,620,000
Surrozen Inc	Opened 87,696	$960,271,000	0.12%
Surrozen Inc	Closed 1,315,463	$644,577,000
No transactions found
Showing first 500 out of 13 holdings